Drugs / Aes-103
Aes-103
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01597401 | May 2012 → Jun 2013 | sickle cell disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01871142 | Mar → Jun 2013 | — | Colorado State University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01987908 | Dec 2013 → Mar 2015 | sickle cell disease | Baxalta now part of Shire | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aes-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01871142 ↗ |
| Known as | 5-(hydroxymethyl)-2-furaldehyde | ChEMBL registry synonym — accepted as the source's own label CHEMBL185885 ↗ |
| Known as | 5-(hydroxymethyl)-2-furancarbonal | ChEMBL registry synonym — accepted as the source's own label CHEMBL185885 ↗ |
| Known as | 5-(hydroxymethyl)-2-furfural | ChEMBL registry synonym — accepted as the source's own label CHEMBL185885 ↗ |
| Known as | 5-hydroxymethyl-2-furfuraldehyde | ChEMBL registry synonym — accepted as the source's own label CHEMBL185885 ↗ |
| Known as | NSC-40738 | ChEMBL registry synonym — accepted as the source's own label CHEMBL185885 ↗ |
| Modality | Small molecule | “a naturally occurring small molecule” NCT01987908 ↗ |
| Route | Oral | “for oral administration” NCT01597401 ↗ |